Advertisement

ASCO GI 2023

IMbrave 151 Missed Primary Endpoint in Advanced BTC

Jan 27, 2023

REFERENCES & ADDITIONAL READING

  1. El-Khoueiry AB, et al. IMbrave151: A phase 2, randomized, double-blind, placebo-controlled study of atezolizumab with or without bevacizumab in combination with cisplatin plus gemcitabine in patients with untreated, advanced biliary tract cancer. Abstract 491, ASCO GI 2023, 19–21 January, San Francisco, CA, USA.

Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement